Drug intelligence / Profile preview

Gynomax

Development stage
Phase 4
Lead developer
Exeltis
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravaginal
01

Overview

Gynomax is a combination intravaginal pharmaceutical product used for the local treatment of vaginal infections, including vulvovaginal candidiasis, bacterial vaginosis, trichomonas vaginitis, and mixed infectious vaginitis. There are several formulations marketed under the name Gynomax or Gynomax XL. The most common formulations contain tinidazole (an antiprotozoal and antibacterial agent), tioconazole (a synthetic antifungal agent), and sometimes lidocaine (a local anesthetic). Some regional variants may also include metronidazole, neomycin sulfate, nystatin, and hydrocortisone acetate[1][2][4][5]. Tinidazole acts by reduction of its nitro group via a ferredoxin-mediated electron transport system in anaerobic organisms; this generates free radicals that bind to DNA causing cell death[8]. Tioconazole inhibits ergosterol synthesis in fungal cell membranes leading to increased permeability and cell death[4]. Lidocaine provides rapid local anesthesia for symptom relief[2][6]. The product is indicated primarily for adult women with vaginal infections caused by susceptible organisms.

Brand names
GynomaxGynomax XL
Other names
tioconazole + tinidazole + lidocaine
02

Targets

CYP51A1 (Sterol 14α-demethylase)NeuraminidaseDNAErgosterolSCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on Gynomax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gynomax.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call